YAbS: The Antibody Society's antibody therapeutics database.

IF 5.6 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

mAbs Pub Date : 2025-12-01 Epub Date: 2025-02-27 DOI:10.1080/19420862.2025.2468845

Puneet Rawat, Silvia Crescioli, R Prabakaran, Divya Sharma, Victor Greiff, Janice M Reichert

{"title":"YAbS: The Antibody Society's antibody therapeutics database.","authors":"Puneet Rawat, Silvia Crescioli, R Prabakaran, Divya Sharma, Victor Greiff, Janice M Reichert","doi":"10.1080/19420862.2025.2468845","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic antibodies have gained prominence in recent years due to their precision in targeting specific diseases. As these molecules become increasingly essential in modern medicine, comprehensive data tracking and analysis are critical for advancing research and ensuring successful clinical outcomes. YAbS, The Antibody Society's Antibody Therapeutics Database, serves as a vital resource for monitoring the development and clinical progress of therapeutic antibodies. The database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that have entered clinical study since 2000, as well as all approved antibody therapeutics. Data for the late-stage clinical pipeline and antibody therapeutics in regulatory review or approved (over 450 molecules) are openly accessible (https://db.antibodysociety.org). Antibody-related information includes molecular format, targeted antigen, current development status, indications studied, and the clinical development timeline of the antibodies, as well as the geographical region of company sponsors. Furthermore, the database supports in-depth industry trends analysis, facilitating the identification of innovative developments and the assessment of success rates within the field. This resource is continually updated and refined, providing invaluable insights to researchers, clinicians, and industry professionals engaged in antibody therapeutics development.</p>","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2468845"},"PeriodicalIF":5.6000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2025.2468845","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Therapeutic antibodies have gained prominence in recent years due to their precision in targeting specific diseases. As these molecules become increasingly essential in modern medicine, comprehensive data tracking and analysis are critical for advancing research and ensuring successful clinical outcomes. YAbS, The Antibody Society's Antibody Therapeutics Database, serves as a vital resource for monitoring the development and clinical progress of therapeutic antibodies. The database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that have entered clinical study since 2000, as well as all approved antibody therapeutics. Data for the late-stage clinical pipeline and antibody therapeutics in regulatory review or approved (over 450 molecules) are openly accessible (https://db.antibodysociety.org). Antibody-related information includes molecular format, targeted antigen, current development status, indications studied, and the clinical development timeline of the antibodies, as well as the geographical region of company sponsors. Furthermore, the database supports in-depth industry trends analysis, facilitating the identification of innovative developments and the assessment of success rates within the field. This resource is continually updated and refined, providing invaluable insights to researchers, clinicians, and industry professionals engaged in antibody therapeutics development.

查看原文本刊更多论文

YAbS：抗体协会的抗体治疗数据库。

近年来，治疗性抗体由于其针对特定疾病的精确性而获得了突出的地位。随着这些分子在现代医学中变得越来越重要，全面的数据跟踪和分析对于推进研究和确保成功的临床结果至关重要。YAbS，抗体协会的抗体治疗数据库，是监测治疗性抗体发展和临床进展的重要资源。该数据库列出了自2000年以来进入临床研究的2,900多种商业资助的研究性抗体候选药物的详细信息，以及所有已批准的抗体治疗方法。后期临床管道和监管审查或批准的抗体治疗（超过450个分子）的数据可公开获取（https://db.antibodysociety.org）。抗体相关信息包括分子格式、靶向抗原、当前开发状态、研究适应症、抗体临床开发时间表以及公司赞助商的地理区域。此外，该数据库支持深入的行业趋势分析，促进识别创新发展和评估该领域的成功率。该资源不断更新和完善，为从事抗体治疗开发的研究人员，临床医生和行业专业人员提供宝贵的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

mAbs 工程技术-仪器仪表

CiteScore

10.70

自引率

11.30%

发文量

审稿时长

6-12 weeks

期刊介绍： mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.